Q4 2024

Filed Mar 3, 2025 · 10-K · 62 days after period end · 0001625297-25-000016

Q4 2024 · 10-K

Revenue

$298.00M

derivedno prior Q4 2023 on file

Net Income

$21.00M

no prior Q4 2023 on file

EPS, diluted—

Gross Profitderived$250,000,000—

Same quarter

no prior Q4 2023 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2024 · filed Mar 3, 2025 · 62 d after period end

Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR